BridgeBio's Heart Disorder Drug Attruby Faces Unanticipated Near-Term Tailwinds, UBS Says
BridgeBio Pharma's (BBIO) heart disorder drug Attruby faces near-term tailwinds from the likely appr
Keep reading this article with Yahoo Finance Plus Silver
Silver
- Premium news Full access to Financial Times and MT Newswires articles
- Stock picks Expert picks from Motley Fool, Zacks, and Moby
- Research reports Expert analysis from Morningstar and Argus
